HC Wainwright Issues Optimistic Estimate for NAGE Earnings

Key Points

• HC Wainwright has revised its Q2 2026 earnings per share estimate for Niagen Bioscience to $0.09, up from $0.08, and maintains a "Buy" rating with a price target of $12.00.
• Niagen Bioscience reported $0.04 earnings per share for the most recent quarter, surpassing analysts' expectations of $0.02, with revenues of $31.12 million against an estimate of $28.55 million.
• Institutional investors have increased their stakes in Niagen Bioscience, with hedge funds collectively owning 15.41% of the company's stock.

Niagen Bioscience, Inc. (NASDAQ:NAGE - Free Report) - Analysts at HC Wainwright upped their Q2 2026 earnings estimates for shares of Niagen Bioscience in a research note issued to investors on Monday, August 11th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn $0.09 per share for the quarter, up from their prior estimate of $0.08. HC Wainwright has a "Buy" rating and a $12.00 price target on the stock. HC Wainwright also issued estimates for Niagen Bioscience's Q3 2026 earnings at $0.11 EPS and FY2026 earnings at $0.40 EPS.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported $0.04 earnings per share for the quarter, topping analysts' consensus estimates of $0.02 by $0.02. Niagen Bioscience had a net margin of 15.24% and a return on equity of 23.12%. The firm had revenue of $31.12 million during the quarter, compared to analyst estimates of $28.55 million.

NAGE has been the subject of a number of other reports. Roth Capital restated a "buy" rating and set a $23.00 price objective (up from $10.00) on shares of Niagen Bioscience in a research note on Friday, June 6th. Canaccord Genuity Group increased their price objective on shares of Niagen Bioscience from $13.00 to $16.00 and gave the stock a "buy" rating in a research note on Tuesday, June 10th. Finally, Wall Street Zen upgraded shares of Niagen Bioscience from a "buy" rating to a "strong-buy" rating in a research note on Saturday. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $13.42.

Niagen Bioscience Trading Up 1.0%

Shares of Niagen Bioscience stock traded up $0.10 during trading hours on Wednesday, reaching $10.12. 965,593 shares of the company's stock were exchanged, compared to its average volume of 951,431. The company has a 50 day moving average of $11.57 and a two-hundred day moving average of $8.44. Niagen Bioscience has a fifty-two week low of $3.10 and a fifty-two week high of $14.69. The stock has a market cap of $807.07 million, a P/E ratio of 48.19 and a beta of 2.12.

Institutional Investors Weigh In On Niagen Bioscience

A number of institutional investors and hedge funds have recently modified their holdings of the company. Geode Capital Management LLC raised its holdings in shares of Niagen Bioscience by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 1,154,778 shares of the company's stock valued at $6,128,000 after purchasing an additional 5,186 shares during the period. D. E. Shaw & Co. Inc. raised its holdings in shares of Niagen Bioscience by 1,785.9% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,011,290 shares of the company's stock valued at $5,365,000 after purchasing an additional 957,665 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Niagen Bioscience by 68.0% in the 4th quarter. Renaissance Technologies LLC now owns 712,788 shares of the company's stock valued at $3,781,000 after purchasing an additional 288,588 shares during the period. Northern Trust Corp raised its holdings in shares of Niagen Bioscience by 13.8% in the 4th quarter. Northern Trust Corp now owns 429,873 shares of the company's stock valued at $2,280,000 after purchasing an additional 52,170 shares during the period. Finally, JPMorgan Chase & Co. raised its holdings in shares of Niagen Bioscience by 2.8% in the 4th quarter. JPMorgan Chase & Co. now owns 341,221 shares of the company's stock valued at $1,810,000 after purchasing an additional 9,305 shares during the period. 15.41% of the stock is owned by institutional investors.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.